Editorial Open Access
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Aug 15, 2024; 16(8): 3382-3385
Published online Aug 15, 2024. doi: 10.4251/wjgo.v16.i8.3382
Importance of early detection of esophageal cancer before the tumor progresses too much for effective treatment
Takashi Ono, Radiation Oncology, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan
ORCID number: Takashi Ono (0000-0002-9711-1158).
Author contributions: Ono T designed the overall concept and outline of the manuscript, wrote, and edited the manuscript and review of literature.
Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Takashi Ono, MD, PhD, Doctor, Radiation Oncology, Faculty of Medicine, Yamagata University, 2-2-2, Iida-Nishi, Yamagata 990-9585, Japan. abc1123513@gmail.com
Received: March 7, 2024
Revised: May 2, 2024
Accepted: May 17, 2024
Published online: August 15, 2024
Processing time: 152 Days and 21.6 Hours

Abstract

This editorial comments on an article by Qu et al published in the World Journal of Gastrointestinal Oncology. It focuses on the importance of early detection of esophageal cancer, including recurrence or secondary malignancy after chemoradiotherapy (CRT). Endoscopic resection is the first choice for treatment for esophageal cancer remaining within the mucous membrane, while surgery or radical CRT are treatment options for advanced stages depending on the patient’s general condition and desire. Although these treatments are potentially curative, they are more invasive than endoscopic resection. Early-stage esophageal cancer is often asymptomatic and difficult to detect. Uniform periodic endoscopy is unrealistic. Although less burdensome tests exist, including liquid biopsy and urinary biomarkers, these have not yet been widely used in clinical practice. Early detection is important after radical CRT because the local recurrence rate is higher than that after surgery. However, endoscopic resection or photodynamic therapy is indicated if detected in the early stages, and positive results have been reported. Early detection of esophageal cancer is crucial. Endoscopy is the main diagnostic method; however, new and less burdensome methods should be established to ensure early treatment for patients with esophageal cancer.

Key Words: Esophageal neoplasms, Screening, Endoscopy, Prognosis, Endoscopic mucosal resection, Endoscopic submucosal dissection, Photodynamic therapy

Core Tip: Surgery and chemoradiotherapy (CRT) for esophageal cancer are more invasive than endoscopic resection. However, early esophageal cancer is often asymptomatic and difficult to detect at an early stage. Uniform periodic endoscopy is unrealistic. This is a challenging problem. Regular endoscopy after CRT is also important, and if detected early, a complete cure can be expected with less burdensome endoscopic treatment. Currently, endoscopy is the main diagnostic method, but the hope is that new and less burdensome diagnostic methods will be established to ensure early treatment.



INTRODUCTION

Esophageal cancer has a poor prognosis and is the sixth leading cause of mortality (544000 deaths annually) globally. For instance, esophageal cancer was responsible for one out of every 18 cancer deaths in 2020[1]. Esophageal cancer is the most common malignancy in Eastern Asia, including China and Japan, with an age-standardized rate of 12.2 per 100000 person-years. This can partly be explained by varying distributions of the two main histologic subtypes of esophageal cancer, namely adenocarcinoma (AC) and squamous cell carcinoma (SCC). The latter histologic subtype is linked to tobacco smoking, heavy alcohol consumption, air pollution, and diet. SCC is the most common, accounting for > 90% of all esophageal cancer cases in high-risk regions. Other contributors to the high incidence observed in some countries remain to be elucidated[2]. The prognosis of SCC and AC differs slightly. The five-year overall survival (OS) rate for patients with SCC and AC was 21.1% and 24.2%, respectively, in 2010. After 1985, the OS rates for AC increased compared to SCC[3]. If patients with stage 1 esophageal cancer do not receive any treatment, the five-year OS rate is only ≤ 10%. Additionally, advanced stages show poorer prognoses[4].

Treatment for esophageal cancer varies depending on the disease progression. Endoscopic resection is recommended for esophageal cancer that remains within the mucosa without lymph node metastasis. In contrast, surgery with or without preoperative chemotherapy or chemoradiotherapy (CRT) is recommended for patients with more advanced-stage and resectable esophageal cancer. Radical CRT is a treatment option if preserving the esophagus is desirable or if surgery is difficult for any reason, such as older age and comorbidities. Radical CRT is indicated for cases of unresectable esophageal cancer[5-8]. Although concurrent chemotherapy is preferred, radiation therapy alone may be curative[9]. Treatment with immune checkpoint inhibitors is indicated as a postoperative treatment after preoperative CRT followed by surgery, and its results are improving[10]. However, patients find themselves with fewer options as the disease progresses towards the discovery stage. This editorial focuses on the importance of early detection of esophageal cancer, including recurrence or secondary malignancy after CRT.

IMPACT OF EARLY DETECTION ON INITIAL TREATMENT

At an early stage, when esophageal cancer remains within the mucous membrane, endoscopic resection, such as endoscopic mucosal resection or endoscopic submucosal dissection, is the first choice for treatment because it requires local excision and imposes the least burden on the patient’s body[5-7]. Surgery requires the removal of the esophagus, resulting in a loss of function. However, with CRT, the esophagus is retained but does not possess the same function as before. Although the decline in quality of life diminishes compared to surgery, especially in terms of loss of appetite and diarrhea, it is not completely eliminated[11]. Proton beam therapy reduces the total toxicity burden by more than half compared to intensity-modulated radiotherapy[12] but is more invasive than endoscopic resection.

The five-year OS rate after endoscopic resection is 87.2%, which is considered a good rate, and is based on actual clinical data, including cases ineligible for clinical trials[9]. Completing the treatment with less invasive methods is important; however, the disease is often asymptomatic in the early stages[2], and detecting the cancerous lesion in a state that can be resected endoscopically without some kind of examination is challenging. The report by Wei et al[13] serves as proof of this concept. In their study, the reduction in cumulative mortality in the intervention and control groups was 3.35% and 5.05%, respectively (P < 0.001)[14]. However, the mortality rate reduction due to intervention is not robust, and routine endoscopy for uniform screening is difficult to recommend in practice. If less invasive tests, such as liquid biopsy and urinary biomarkers are established as previous studies[14-16] and Qu et al[17] said, identifying separate groups for which endoscopy should be performed may be possible, allowing the realization of more realistic screening methods.

IMPORTANCE OF REGULAR ENDOSCOPY AFTER CRT FOR EARLY DETECTION

Early detection is important for initial treatment and recurrence or secondary malignancy after radical CRT. Local recurrence is inevitably more common after CRT than after surgery, posing a significant problem. A clinical trial revealed that the local recurrence rate within the irradiation field was 15.1% in stage 1[18] and increased to 32% in stage 2/3[19]. Even in rigorous clinical trials, the incidence of treatment-related death after salvage surgery was 4%[19]. In a systematic review, the treatment-related death rate after salvage surgery for recurrence after CRT was reported at 10.3%[20]. After salvage surgery, the three-year OS was only 33.5%, and 9.6% of patients experienced grade 3 toxicities, including anastomosis leak[18].

In contrast, the five-year OS rate was 49.1%, with no severe toxicity after salvage endoscopic mucosal resection for recurrence after CRT[21]. Photodynamic therapy, which is considered more useful than endoscopic resection, is indicated if local recurrence occurs without lymph node metastasis and the invasion of the muscularis mucosae. This treatment’s local complete response rate is 58.4%, and the five-year OS rate is 35.9%[22]. This treatment is less invasive than salvage surgery; however, the tumor must be detected early before its progression. Sudo et al[23] reported that 93% of cases of local recurrence after radical CRT were diagnosed within three years. The annual odds of a secondary malignancy diagnosed using endoscopy did not decrease over time. These results indicate the need to exercise caution during the first three years after radical CRT; however, even after three years, regular endoscopy is necessary to detect secondary malignancy before it advances.

CONCLUSION

Early detection of esophageal cancer is crucial. Endoscopy is the main diagnostic method; however, new and less burdensome diagnostic methods should be established to ensure early treatment for patients with esophageal cancer.

Footnotes

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Oncology

Country of origin: Japan

Peer-review report’s classification

Scientific Quality: Grade B, Grade B

Novelty: Grade B, Grade C

Creativity or Innovation: Grade B, Grade C

Scientific Significance: Grade B, Grade B

P-Reviewer: Gragnaniello V, Italy; Liu Y, China S-Editor: Wang JJ L-Editor: A P-Editor: Cai YX

References
1.  Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209-249.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 50630]  [Cited by in F6Publishing: 48984]  [Article Influence: 16328.0]  [Reference Citation Analysis (121)]
2.  Arnold M, Abnet CC, Neale RE, Vignat J, Giovannucci EL, McGlynn KA, Bray F. Global Burden of 5 Major Types of Gastrointestinal Cancer. Gastroenterology. 2020;159:335-349.e15.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 857]  [Cited by in F6Publishing: 870]  [Article Influence: 217.5]  [Reference Citation Analysis (0)]
3.  He H, Chen N, Hou Y, Wang Z, Zhang Y, Zhang G, Fu J. Trends in the incidence and survival of patients with esophageal cancer: A SEER database analysis. Thorac Cancer. 2020;11:1121-1128.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 37]  [Cited by in F6Publishing: 84]  [Article Influence: 21.0]  [Reference Citation Analysis (0)]
4.  Keshava HB, Rosen JE, DeLuzio MR, Kim AW, Detterbeck FC, Boffa DJ. "What if I do nothing?" The natural history of operable cancer of the alimentary tract. Eur J Surg Oncol. 2017;43:788-795.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 7]  [Cited by in F6Publishing: 7]  [Article Influence: 1.0]  [Reference Citation Analysis (0)]
5.  Obermannová R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M, van Grieken NCT, Vogel A, Smyth EC; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:992-1004.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 82]  [Cited by in F6Publishing: 159]  [Article Influence: 79.5]  [Reference Citation Analysis (0)]
6.  Porschen R, Fischbach W, Gockel I, Hollerbach S, Hölscher A, Jansen PL, Miehlke S, Pech O, Stahl M, Vanhoefer U, Ebert MPA. Updated German guideline on diagnosis and treatment of squamous cell carcinoma and adenocarcinoma of the esophagus. United European Gastroenterol J. 2024;12:399-411.  [PubMed]  [DOI]  [Cited in This Article: ]  [Reference Citation Analysis (0)]
7.  Kitagawa Y, Uno T, Oyama T, Kato K, Kato H, Kawakubo H, Kawamura O, Kusano M, Kuwano H, Takeuchi H, Toh Y, Doki Y, Naomoto Y, Nemoto K, Booka E, Matsubara H, Miyazaki T, Muto M, Yanagisawa A, Yoshida M. Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1. Esophagus. 2019;16:1-24.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 285]  [Cited by in F6Publishing: 345]  [Article Influence: 69.0]  [Reference Citation Analysis (0)]
8.  Kato K, Ito Y, Daiko H, Ozawa S, Ogata T, Hara H, Kojima T, Abe T, Bamba T, Watanabe M, Kawakubo H, Shibuya Y, Tsubosa Y, Takegawa N, Kajiwara T, Baba H, Ueno M, Machida R, Nakamura K, Kitagawa Y. A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study. J Clin Oncol. 2022;40:238.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 13]  [Cited by in F6Publishing: 17]  [Article Influence: 8.5]  [Reference Citation Analysis (0)]
9.  Watanabe M, Toh Y, Ishihara R, Kono K, Matsubara H, Miyazaki T, Morita M, Murakami K, Muro K, Numasaki H, Oyama T, Saeki H, Tanaka K, Tsushima T, Ueno M, Uno T, Yoshio T, Usune S, Takahashi A, Miyata H; Registration Committee for Esophageal Cancer of the Japan Esophageal Society. Comprehensive registry of esophageal cancer in Japan, 2015. Esophagus. 2023;20:1-28.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 20]  [Reference Citation Analysis (0)]
10.  Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, Mendez G, Feliciano J, Motoyama S, Lièvre A, Uronis H, Elimova E, Grootscholten C, Geboes K, Zafar S, Snow S, Ko AH, Feeney K, Schenker M, Kocon P, Zhang J, Zhu L, Lei M, Singh P, Kondo K, Cleary JM, Moehler M; CheckMate 577 Investigators. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med. 2021;384:1191-1203.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 469]  [Cited by in F6Publishing: 783]  [Article Influence: 261.0]  [Reference Citation Analysis (0)]
11.  Ariga H, Nemoto K, Miyazaki S, Yoshioka T, Ogawa Y, Sakayauchi T, Jingu K, Miyata G, Onodera K, Ichikawa H, Kamei T, Kato S, Ishioka C, Satomi S, Yamada S. Prospective comparison of surgery alone and chemoradiotherapy with selective surgery in resectable squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 2009;75:348-356.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 74]  [Cited by in F6Publishing: 80]  [Article Influence: 5.3]  [Reference Citation Analysis (0)]
12.  Lin SH, Hobbs BP, Verma V, Tidwell RS, Smith GL, Lei X, Corsini EM, Mok I, Wei X, Yao L, Wang X, Komaki RU, Chang JY, Chun SG, Jeter MD, Swisher SG, Ajani JA, Blum-Murphy M, Vaporciyan AA, Mehran RJ, Koong AC, Gandhi SJ, Hofstetter WL, Hong TS, Delaney TF, Liao Z, Mohan R. Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. J Clin Oncol. 2020;38:1569-1579.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 98]  [Cited by in F6Publishing: 153]  [Article Influence: 38.3]  [Reference Citation Analysis (0)]
13.  Wei WQ, Chen ZF, He YT, Feng H, Hou J, Lin DM, Li XQ, Guo CL, Li SS, Wang GQ, Dong ZW, Abnet CC, Qiao YL. Long-Term Follow-Up of a Community Assignment, One-Time Endoscopic Screening Study of Esophageal Cancer in China. J Clin Oncol. 2015;33:1951-1957.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 159]  [Cited by in F6Publishing: 222]  [Article Influence: 24.7]  [Reference Citation Analysis (0)]
14.  Yuan Z, Wang X, Geng X, Li Y, Mu J, Tan F, Xue Q, Gao S, He J. Liquid biopsy for esophageal cancer: Is detection of circulating cell-free DNA as a biomarker feasible? Cancer Commun (Lond). 2021;41:3-15.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 3]  [Cited by in F6Publishing: 8]  [Article Influence: 2.0]  [Reference Citation Analysis (0)]
15.  Okuda Y, Shimura T, Iwasaki H, Fukusada S, Nishigaki R, Kitagawa M, Katano T, Okamoto Y, Yamada T, Horike SI, Kataoka H. Urinary microRNA biomarkers for detecting the presence of esophageal cancer. Sci Rep. 2021;11:8508.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 6]  [Cited by in F6Publishing: 7]  [Article Influence: 2.3]  [Reference Citation Analysis (0)]
16.  Chidambaram S, Markar SR. Clinical utility and applicability of circulating tumor DNA testing in esophageal cancer: a systematic review and meta-analysis. Dis Esophagus. 2022;35.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 4]  [Cited by in F6Publishing: 9]  [Article Influence: 3.0]  [Reference Citation Analysis (0)]
17.  Qu HT, Li Q, Hao L, Ni YJ, Luan WY, Yang Z, Chen XD, Zhang TT, Miao YD, Zhang F. Esophageal cancer screening, early detection and treatment: Current insights and future directions. World J Gastrointest Oncol. 2024;16:1180-1191.  [PubMed]  [DOI]  [Cited in This Article: ]  [Reference Citation Analysis (0)]
18.  Kato K, Ito Y, Nozaki I, Daiko H, Kojima T, Yano M, Ueno M, Nakagawa S, Takagi M, Tsunoda S, Abe T, Nakamura T, Okada M, Toh Y, Shibuya Y, Yamamoto S, Katayama H, Nakamura K, Kitagawa Y; Japan Esophageal Oncology Group of the Japan Clinical Oncology Group. Parallel-Group Controlled Trial of Surgery Versus Chemoradiotherapy in Patients With Stage I Esophageal Squamous Cell Carcinoma. Gastroenterology. 2021;161:1878-1886.e2.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 21]  [Cited by in F6Publishing: 46]  [Article Influence: 15.3]  [Reference Citation Analysis (0)]
19.  Takeuchi H, Ito Y, Machida R, Kato K, Onozawa M, Minashi K, Yano T, Nakamura K, Tsushima T, Hara H, Okuno T, Hironaka S, Nozaki I, Ura T, Chin K, Kojima T, Seki S, Sakanaka K, Fukuda H, Kitagawa Y; Japan Esophageal Oncology Group of the Japan Clinical Oncology Group. A Single-Arm Confirmatory Study of Definitive Chemoradiation Therapy Including Salvage Treatment for Clinical Stage II/III Esophageal Squamous Cell Carcinoma (JCOG0909 Study). Int J Radiat Oncol Biol Phys. 2022;114:454-462.  [PubMed]  [DOI]  [Cited in This Article: ]  [Reference Citation Analysis (0)]
20.  Kumagai K, Mariosa D, Tsai JA, Nilsson M, Ye W, Lundell L, Rouvelas I. Systematic review and meta-analysis on the significance of salvage esophagectomy for persistent or recurrent esophageal squamous cell carcinoma after definitive chemoradiotherapy. Dis Esophagus. 2016;29:734-739.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 29]  [Cited by in F6Publishing: 29]  [Article Influence: 3.6]  [Reference Citation Analysis (0)]
21.  Yano T, Muto M, Hattori S, Minashi K, Onozawa M, Nihei K, Ishikura S, Ohtsu A, Yoshida S. Long-term results of salvage endoscopic mucosal resection in patients with local failure after definitive chemoradiotherapy for esophageal squamous cell carcinoma. Endoscopy. 2008;40:717-721.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 77]  [Cited by in F6Publishing: 80]  [Article Influence: 5.0]  [Reference Citation Analysis (0)]
22.  Hatogai K, Yano T, Kojima T, Onozawa M, Daiko H, Nomura S, Yoda Y, Doi T, Kaneko K, Ohtsu A. Salvage photodynamic therapy for local failure after chemoradiotherapy for esophageal squamous cell carcinoma. Gastrointest Endosc. 2016;83:1130-1139.e3.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 28]  [Cited by in F6Publishing: 27]  [Article Influence: 3.4]  [Reference Citation Analysis (0)]
23.  Sudo K, Kato K, Kuwabara H, Sasaki Y, Takahashi N, Shoji H, Iwasa S, Honma Y, Okita NT, Takashima A, Hamaguchi T, Yamada Y, Ito Y, Itami J, Fukuda T, Tobinai K, Boku N. Patterns of Relapse after Definitive Chemoradiotherapy in Stage II/III (Non-T4) Esophageal Squamous Cell Carcinoma. Oncology. 2018;94:47-54.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 7]  [Cited by in F6Publishing: 10]  [Article Influence: 1.4]  [Reference Citation Analysis (0)]